Table 1.
Basic characteristics and treatment regimens of the patients with or without hepatocellular carcinoma (HCC)
| All patients (n=713) |
Non-HCC (n=601) |
HCC (n=112) |
P value | |
| Male, n (%) | 291 (40.8) | 240 (39.9) | 51 (45.5) | 0.27 |
| Age, years (mean±SD) | 62.2±11.3 | 61.2±11.4 | 67.6±9.0 | <0.001 |
| Body weight, kg (mean±SD) | 64.0±12.5 | 64.3±12.8 | 62.4±10.6 | 0.15 |
| Diabetes, n (%) | 163 (22.9) | 137 (22.8) | 26 (23.2) | 0.92 |
| Platelet count, ×1000/10/L (mean±SD) | 161±70 | 166±70 | 133±73 | <0.001 |
| AST, IU/L (mean±SD) | 73.9±48.7 | 71.6±46.3 | 86.7±58.5 | 0.003 |
| ALT, IU/L (mean±SD) | 83.2±60.2 | 83.5±61.0 | 81.9±56.2 | 0.79 |
| Serum albumin, g/dL (mean±SD) | 4.2±0.4 | 4.3±0.4 | 4.0±0.5 | <0.001 |
| Serum bilirubin, mg/dL (mean±SD) | 0.97+0.51 | 0.94±0.50 | 1.14+0.56 | <0.001 |
| Creatinine, mg/dL (mean±SD) | 1.00±1.14 | 0.97±1.11 | 1.12±1.31 | 0.27 |
| HCV RNA, log IU/mL | 5.78±0.92 | 5.81±0.92 | 5.62±0.92 | 0.05 |
| HCV genotype, n (%) | ||||
| 1 | 618 (86.7) | 520 (86.5) | 98 (87.5) | 0.78 |
| 2 | 95 (13.3) | 81 (13.5) | 14 (12.5) | |
| Liver cirrhosis, n (%) | 368 (51.6) | 276 (45.9) | 92 (82.1) | <0.001 |
| Child-Pugh A/B, n (%) | 339 (47.5)/29 (4.1) | 256 (42.6)/20 (3.3) | 83 (74.1)/9 (8.0) | 0.43 |
| Prior treatment experienced*, n (%) | 284 (39.8) | 227 (37.8) | 57 (50.9) | 0.009 |
| Post liver transplantation, n (%) | 13 (1.8) | 7 (1.2) | 6 (5.4) | 0.009 |
| Regimen, n (%) | 0.74 | |||
| PrOD±RBV | 463 (64.9) | 393 (65.4) | 70 (62.5) | |
| DCV/ASV | 91 (12.8) | 76 (12.6) | 15 (13.4) | |
| SOF/RBV | 41 (5.8) | 37 (6.2) | 4 (3.6) | |
| SOF/LDV±RBV | 58 (8.1) | 47 (7.8) | 11 (9.8) | |
| SOF/DCV±RBV | 47 (6.6) | 37 (6.2) | 10 (8.9) | |
| EBR/GZR | 10 (1.4) | 8 (1.3) | 2 (1.8) | |
| SOF/VEL | 3 (0.4) | 3 (0.5) | 0 (0) |
*All interferon-based therapy.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ASV, asunaprevir; DCV, daclatasvir; EBR, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; LDV, ledipasvir; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir.